Loading…
An optimization algorithm for designing phase I cancer clinical trials
Abstract Numerous phase I dose finding clinical trials are conducted everyday to find the “maximum tolerated dose” (MTD) of a cancer treatment. Although various Bayesian designs for Phase I clinical trials have been proposed in the literature, the traditional 3 + 3 design is still widely used becaus...
Saved in:
Published in: | Contemporary clinical trials 2008-03, Vol.29 (2), p.102-108 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Abstract Numerous phase I dose finding clinical trials are conducted everyday to find the “maximum tolerated dose” (MTD) of a cancer treatment. Although various Bayesian designs for Phase I clinical trials have been proposed in the literature, the traditional 3 + 3 design is still widely used because of its algorithm-based simplicity in logistics for the clinical investigators to carry out in comparison with model-based Bayesian methods. In this paper, we propose an optimization algorithm for designing phase I cancer clinical trials. This algorithm does not need assumptions on the true dose-response relationship but can readily incorporate available prior information about the true response probabilities. It searches for an approximately optimal design within a design space, in which the 3 + 3 design is included as a special case. Simulation studies show that the design recommended by this algorithm significantly outperforms the 3 + 3 design. |
---|---|
ISSN: | 1551-7144 1559-2030 |
DOI: | 10.1016/j.cct.2007.06.003 |